| REVENUES |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2025 |
|
2024 |
Product sales: |
|
|
|
|
|
|
Gross product sales |
|
$ |
60,192 |
|
$ |
38,426 |
Discounts and allowances |
|
|
(16,642) |
|
|
(12,423) |
Total product sales, net |
|
|
43,550 |
|
|
26,003 |
Revenues from collaborations: |
|
|
|
|
|
|
Milestone revenue |
|
|
3,000 |
|
|
— |
Delivery of drug supplies, royalty and others |
|
|
6,783 |
|
|
3,531 |
Total revenues from collaborations |
|
|
9,783 |
|
|
3,531 |
Total revenues |
|
$ |
53,333 |
|
$ |
29,534 |
Revenue from product sales is related to sales of our commercial products to our customers. For detailed discussions of our revenues from collaborations and government contracts, see “Note 4 – Sponsored Research, License Agreements and Government Contracts.”
Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. Of the total discounts and allowances from gross product sales for the three months ended March 31, 2025 and 2024, $16.1 million and $12.3 million, respectively, was accounted for as additions to revenue reserves and refund liability, and $0.5 million and $0.1 million, respectively, as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet.
The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2025 |
|
$ |
13,374 |
|
$ |
8,343 |
|
$ |
4,723 |
|
$ |
26,440 |
Provision related to current period sales |
|
|
12,811 |
|
|
3,654 |
|
|
398 |
|
|
16,863 |
Adjustment related to prior period sales |
|
|
— |
|
|
(148) |
|
|
(560) |
|
|
(708) |
Credit or payments made during the period |
|
|
(12,928) |
|
|
(1,669) |
|
|
(63) |
|
|
(14,660) |
Balance as of March 31, 2025 |
|
$ |
13,257 |
|
$ |
10,180 |
|
$ |
4,498 |
|
$ |
27,935 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2024 |
|
$ |
8,236 |
|
$ |
3,517 |
|
$ |
3,931 |
|
$ |
15,684 |
Provision related to current period sales |
|
|
9,763 |
|
|
2,280 |
|
|
224 |
|
|
12,267 |
Credit or payments made during the period |
|
|
(10,255) |
|
|
(1,609) |
|
|
(42) |
|
|
(11,906) |
Balance as of March 31, 2024 |
|
$ |
7,744 |
|
$ |
4,188 |
|
$ |
4,113 |
|
$ |
16,045 |
The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2025 |
|
2024 |
McKesson Corporation |
|
|
42% |
|
|
42% |
Cencora Inc. (formerly ASD Healthcare) |
|
|
20% |
|
|
23% |
Optime Care, Inc. |
|
|
11% |
|
|
* |
Cardinal Health, Inc. |
|
|
* |
|
|
23% |
*Denotes less than 10%
|